Patents by Inventor Duane Eugene DeMong

Duane Eugene DeMong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
    Patent number: 8735604
    Abstract: The present invention relates to compounds of the general formula: (I) wherein ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: May 27, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric J. Gilbert, Michael W. Miller, Duane Eugene DeMong, Andrew W. Stamford, William J. Greenlee
  • Substituted piperazines as CB1 antagonists
    Patent number: 8623873
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: January 7, 2014
    Assignee: Intervet Inc.
    Inventors: Eric J. Gilbert, Michael W. Miller, Jack D. Scott, Duane Eugene DeMong, Andrew Stamford, William J. Greenlee, Chander Shekher Celly
  • Glucagon receptor antagonists, compositions, and methods for their use
    Patent number: 8623818
    Abstract: The present invention relates to compounds of general formula (I), wherein ring A, ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: January 7, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: William J. Greenlee, Andrew Stamford, Michael W. Miller, Duane Eugene DeMong
  • Spiro-imidazolone derivatives as glucagon receptor antagonists
    Patent number: 8361959
    Abstract: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: January 29, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew Stamford, Michael W. Miller, Duane Eugene DeMong, William J. Greenlee, Joseph A. Kozlowski, Brian J. Lavey, Michael K. C. Wong, Wensheng Yu, Xing Dai, De-Yi Yang, Guowei Zhou
  • NOVEL PYRROLIDINES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE
    Publication number: 20120178789
    Abstract: The present invention relates to compounds of the general formula: (I) wherein ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Application
    Filed: September 16, 2010
    Publication date: July 12, 2012
    Inventors: Eric J. Gilbert, Michael W. Miller, Duane Eugene DeMong, Andrew W. Stamford, William J. Greenlee
  • SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS
    Publication number: 20110178007
    Abstract: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Application
    Filed: September 30, 2009
    Publication date: July 21, 2011
    Inventors: Andrew Stamford, Michael W Miller, Duane Eugene Demong, William J Greenlee, Joseph A Kozlowski, Brian J Lavey, Michael K.C. Wong, Wensheng Yu, Xing Dai, De-Yi Yang, Guowei Zhou
  • GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE
    Publication number: 20110065634
    Abstract: The present invention relates to compounds of general formula (I), wherein ring A, ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Application
    Filed: May 13, 2009
    Publication date: March 17, 2011
    Inventors: William J. Greenlee, Andrew Stamford, Michael W. Miller, Duane Eugene DeMong
  • SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS
    Publication number: 20100249144
    Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Application
    Filed: June 25, 2008
    Publication date: September 30, 2010
    Inventors: Duane Eugene Demong, Michael W. Miller, Eric J. Gilbert, Jack D. Scott, Andrew Stamford, William J. Greenlee, Chander Shekher Celly
  • Substituted Piperazines as CB1 Antagonists
    Publication number: 20090105208
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
    Type: Application
    Filed: June 25, 2008
    Publication date: April 23, 2009
    Inventors: Eric J. Gilbert, Michael W. Miller, Jack D. Scott, Duane Eugene DeMong, Andrew Stamford, William J. Greenlee, Chander Shekher Celly